Arix invests in innovative Life Science companies and are instrumental in addressing patient needs.

Sectors icon


Financial Services

Disciplines icon


Graphic Design
Printed Annual Report


With a year of continued rapid growth, in which seven new investments were made, it was important to communicate the year’s successes and present the investment case clearly to a range of stakeholders from professional investors, to doctors who support their work and individuals who have been affected by diseases that their companies are looking to cure.


The main aim of the company is to provide support to young developing life science companies and invest in their potential. In this year's report, the design and content needed to highlight the new investments made over the year. As an example, Aura Biosciences, one of these new investments, targets ocular melanoma, a rare and aggressive eye cancer which represents a significant unmet need. Aura is creating a new class of therapies that can pinpoint solid tumours without harming surrounding tissue, enabling targeted treatment across a wide range of cancers.

Another key consideration was the design of this years report, ensuring it was consistent with the brand style. To create an overall visually engaging report, full-page images were used throughout and the use of white space ensures that it follows a clean design. Case studies based on new investments follow this thread, using full-page imagery and a top-level overview to enhance the clean, engaging design.

The business model ensures that the investment proposition is clearly communicated and incorporates case studies to allow stakeholders to see the model in action.


The report clearly communicates the growth and investments made over the year and works to clearly articulate Arix Bioscience's value proposition to a range of stakeholders utilising key case studies, a clear business model and well-considered design.

Download PDF

Keep up to date

Our latest opinions